MARKET

SGEN

SGEN

Seagen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

162.51
+1.17
+0.73%
Closed 16:20 09/27 EDT
OPEN
160.98
PREV CLOSE
161.34
HIGH
162.80
LOW
159.09
VOLUME
699.78K
TURNOVER
--
52 WEEK HIGH
213.94
52 WEEK LOW
133.20
MARKET CAP
29.57B
P/E (TTM)
49.87
1D
5D
1M
3M
1Y
5Y
RBC Capital Maintains Sector Perform on Seagen, Raises Price Target to $154
RBC Capital analyst Kennen MacKay maintains Seagen (NASDAQ:SGEN) with a Sector Perform and raises the price target from $148 to $154.
Benzinga · 23h ago
RBC Boosts Price Target on Seagen to $154 From $148 Amid Tivdak US Approval, Combination Therapy Potential; Sector Perform Kept
MT Newswires · 1d ago
Japan's MHLW Approves PADCEV(R) (enfortumab vedotin) for Advanced Urothelial Cancer
Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved PADCEV(R) (enfortumab vedotin) for radically unresec...
Business Wire · 1d ago
Seagen's Urothelial Cancer Drug Padcev Gets Japanese Regulator's Approval
MT Newswires · 1d ago
Guggenheim Adjusts Price Target on Seagen to $193 From $200, Maintains Buy Rating
MT Newswires · 5d ago
Goldman Sachs Adjusts Price Target on Seagen to $222 From $223, Maintains Buy Rating
MT Newswires · 5d ago
Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA
Zacks.com · 5d ago
SVB Leerink Adjusts Seagen's Price Target to $190 from $192, Keeps Outperform Rating
MT Newswires · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SGEN. Analyze the recent business situations of Seagen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

26.32%Strong Buy
31.58%Buy
42.11%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SGEN stock price target is 188.00 with a high estimate of 254.00 and a low estimate of 154.00.
High254.00
Average188.00
Low154.00
Current 162.51
EPS
Actual
Estimate
0.341.352.363.37
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 644
Institutional Holdings: 170.61M
% Owned: 93.78%
Shares Outstanding: 181.93M
TypeInstitutionsShares
Increased
183
9.08M
New
42
1.23M
Decreased
161
5.39M
Sold Out
62
2.69M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.10%
Pharmaceuticals & Medical Research
-0.86%
Key Executives
Chairman/Director/President/Chief Executive Officer
Clay Siegall
Chief Financial Officer
Todd Simpson
Executive Vice President/General Counsel/Secretary
Jean Liu
Executive Vice President
Chip Romp
Chief Technology Officer
Vaughn Himes
Other
Roger Dansey
Lead Director/Independent Director
Felix Baker
Independent Director
David Gryska
Independent Director
Marc Lippman
Independent Director
Ted Love
Independent Director
John Orwin
Independent Director
Alpna Seth
Independent Director
Nancy Simonian
Independent Director
Daniel Welch
No Data
About SGEN
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The Company is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The Company also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The Company's approved medicines include ADCETRIS, PADCEV and TUKYSA.

Webull offers kinds of Seagen Inc stock information, including NASDAQ:SGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SGEN stock methods without spending real money on the virtual paper trading platform.